Objective: To assess the outcome of elderly patients with primary CNS lymphoma (PCNSL) treated within the G-PCNSL-SG-1 trial.
Primary CNS lymphoma (PCNSL) is a rare brain tumor and higher age has repeatedly been noted as a major negative prognostic factor associated with inferior survival and increased risk of (neuro)toxicity. 1, 2 Only few trials for elderly patients with PCNSL have been conducted. [3] [4] [5] [6] [7] [8] [9] The concept of whole brain radiotherapy (WBRT) alone has been abandoned in favor of HD-MTX-based regimens. 3, 10, 11 Various regimens consisting of HD-MTX alone or in combination with other chemotherapeutic drugs or WBRT have been applied. No convincing therapeutic strategy is available for patients who cannot be treated with HD-MTX. 9 The activity of novel therapeutic agents such as rituximab in young and elderly patients with PCNSL is still under debate. 8, 12 The G-PCNSL-SG-1 trial recently indicated that the omission of WBRT from the treatment of newly diagnosed PCNSL does not compromise overall survival (OS). 13 This trial had randomized the patients after diagnosis to receive, after HD-MTX-based chemotherapy, either consolidation (for complete response [CR] patients) or salvage (for non-CR patients) WBRT vs wait-and-see (CR patients) or salvage HDcytarabine chemotherapy (non-CR patients). Meanwhile, a consensus has been reached that future trials should consider age as a stratification factor where more aggressive approaches with a curative approach should be administered to younger patients whereas the focus in the elderly patients should be on maintaining remission and increasing tolerability. Here we provide an analysis of the impact of higher age defined as 70 or more on response to therapy, toxicity, and survival in the largest PCNSL trial ever performed to date.
METHODS Patients.
In this post hoc analysis, the study population of the G-PCNSL-SG-1 trial was divided arbitrarily into 2 groups with a cutoff of 70 years or older vs younger than 70 years. We considered 4 patient populations: 1) all patients who fulfilled the inclusion criteria and received at least 1 cycle of HD-MTX-based chemotherapy (n ϭ 526); 2) the patients who started HD-MTX-based chemotherapy but did not enter the randomized treatment phase (all patients minus intention-totreat [ITT], n ϭ 115), and within the ITT population 411 patients of the second phase separately; 3) the per protocol (PP) population (n ϭ 318); and 4) the patients of the ITT population who were not treated as randomized after HD-MTX-based chemotherapy (n ϭ 93). The latter population of 93 patients includes 29 patients with CR who were randomized to receive WBRT but did not, 20 patients without CR who were randomized to receive WBRT but did not, and 44 patients randomized to high-dose Ara-C who were treated otherwise or not at all. This population was analyzed here separately to reflect a possible bias introduced by reporting the PP as opposed to the ITT population as outlined earlier. 13 The definition of populations was done in a blind data review, not taking into account patients' outcome.
Statistical analysis. Chi-square tests were used for comparisons of categorical variables; response was treated as an ordinal variable and tested with 1 degree of freedom (Mantel-Haenszel 2 for "linear by linear association"). Survival was analyzed by the Kaplan-Meier method including the log-rank test and by Cox proportional odds model. The importance of prognostic factors was compared between younger and elder patients using interaction terms in the Cox model. Since this was an exploratory analysis, significance testing was performed for each variable of interest separately. No adjustment for multiple testing was applied. The level of significance was 0.05 (2-sided) for each test. Based on the number of observed events, hazard ratios of at least 1.4 to 1.7 could be detected with a power of 80% in the 3 populations (eligible, ITT; PP) ignoring multiplicity and the post hoc nature of the study. Commercially available software (SPSS for Windows, 18.0) was used.
RESULTS Patient characteristics.
The baseline characteristics such as type of surgery, neuropathologic diagnosis, neuroimaging, Karnofsky Performance Score, lactate dehydrogenase levels, CSF and ocular involvement were similar in elderly and younger patients in all 4 sets of patients: all patients who fulfilled the inclusion criteria and received at least 1 cycle of HD-MTX-based chemotherapy (n ϭ 526), all patients minus the ITT population (n ϭ 115), the PP population (n ϭ 318), and the ITT patients who were not treated PP (n ϭ 93) (table e-1 on the Neurology ® Web site at www.neurology.org). The proportion of elderly patients was highest (37%) in the non-ITT population of 115 patients. In younger patients, the male/female ratio was very similar across all 4 subpopulations. In contrast, for the elder patients, the male/female ratio was higher in the PP population (38 vs 28 patients, 58% vs 42%) than in the other 208 patients comprising all patients minus the ITT population (n ϭ 115) plus the ITT patients who were not treated PP (n ϭ 93) (25 vs 35 patients, 42% vs 58%) ( 2 test, p ϭ 0.074).
Response to HD-MTX-based chemotherapy. Table 1 summarizes the response to HD-MTX-based chemotherapy. In the primary eligibility population of 526 patients, elderly patients had a lower rate of complete and partial responses (44% vs 57%, p ϭ 0.016), died more often during the initial phase of HD-MTXbased chemotherapy (18% vs 11%, p ϭ 0.027) (see below), and had more often an unknown remission status (12% vs 4%, p ϭ 0.001). In the cohort of patients who started HD-MTX-based chemotherapy but did not enter the second, randomized part of the trial (n ϭ 115), remission status was also more often unknown in the elderly population (35% vs 21%, p ϭ 0.125). In contrast, younger and elderly patients in the PP population of 318 patients showed almost identical percentages of CR, PR, SD, or PD, respectively. Of note, among the 93 patients of the ITT patients who were not treated PP, the combined CR/PR rate with HD-MTX-based chemotherapy was 35% in the elder vs 61% in the younger patients (7) 47 (12) 3 (7) 7 (10) 4 (6) 25 (10) 2 (12) 15 (20) 4 11 (9) 29 (7) 1 (2) 2 (3) 9 (14) 22 (9) 1 (6) Abbreviations: CI ϭ confidence interval; ITT ϭ intention-to-treat; PP ϭ per protocol. a Data are absolute frequency (%); denominators are provided when data were not available for all patients.
( p ϭ 0.058). In other words, patients with PD were less likely to be treated as randomized when they were 70 or older.
Toxicity of HD-MTX-based chemotherapy. Hematologic toxicity was similar in both patient groups defined by age except for grade III/IV leukopenia which was more common in elderly patients (34% vs 21%, p ϭ 0.007) (table 1). Nonhematologic toxicity was also similar in both patient groups. There were trends for higher toxicity in the elderly population, but the differences did not reach significance (table 1) . Overall, MTX dose was reduced more frequently in the elderly population. In patients aged 70 or older the median MTX dose administered was lower than in the younger patients across all populations analyzed (table  2) . In contrast, delayed MTX application was similarly frequent in older and young patients. Causes of death among younger patients (n ϭ 43) during HD-MTXbased chemotherapy were PD (n ϭ 18), myelosuppression or infection (n ϭ 12), toxicity (n ϭ 5), and others (n ϭ 8), as opposed to PD (n ϭ 6), myelosuppression or infection (n ϭ 8), toxicity (n ϭ 3), and others (n ϭ 6). There were thus trends for more deaths from toxicity ( p ϭ 0.022) and myelosuppression or infection ( p ϭ 0.11) in the elderly.
Treatment at recurrence. The ITT population was used for the analysis of salvage treatments. Patients aged 70 or older were more likely to receive no salvage therapy than younger patients. In the younger population, chemotherapy or a combination of radio-and chemotherapy were more commonly applied than in elderly patients whereas the frequency of radiotherapy was comparable for both age groups (table 3) . Patients who received salvage chemotherapy, either alone or in combination with irradiation, were treated with various regimens including topotecan, cytarabine, and CHOP without major differences between young and old patients.
Survival.
For the eligibility population of 526 patients, PFS was longer in the younger patients (7.7 vs 4.0 months, p ϭ 0.01), and this difference became even more prominent when looking at OS (26.2 vs 12.5 months, p Ͻ 0.001) (table 4, figure, A and B) .
In the smaller ITT minus PP population of 93 patients, the differences were not statistically different and of comparable magnitude: 6.4 vs 3.3 months ( p ϭ 0.86) for PFS and 32.1 vs 12.9 months for OS ( p ϭ 0.24).
Within the PP population of 318 patients which represents a positive patient selection relative to the primary eligibility population of 526 patients, 13 PFS was not significantly longer in younger than in elderly patients (15.4 vs 13.6 months, p ϭ 0.25). However, a major difference became apparent when PFS was analyzed by response to HD-MTX-based chemotherapy: both age groups had a median PFS below 4 months when patients achieving PR, SD, or PD were considered alone. In contrast, the PFS in younger patients with a CR was 35.0 months as opposed to 16.1 months in the elder patients ( p ϭ 0.024). Age was a relevant prognostic factor for CR patients with and without WBRT (table 4, figure, C-F). We also considered specifically the patients of the PP population who experienced PD during primary chemotherapy and were subsequently treated with WBRT. The survival from the diagnosis of PD was 11 in the younger (n ϭ 33) vs 13.2 months (n ϭ 12) in the elderly patients ( p ϭ 0.633).
OS analyses in the PP population also revealed a strong difference of outcome by age: OS was significantly longer in younger than in elderly patients (37.1 vs 22.4 months, p ϭ 0.015) (table 4). Patients with CR to HD-MTX-based chemotherapy accounted for this difference in outcome (44.2 vs 26.7 months, p ϭ 0.006) whereas OS was similar in patients failing to achieve a CR (22.3 vs 17.3 months, p ϭ 0.28). However, both for OS and PFS the statistical interaction term between response and age was not significant in the Cox regression model (p ϭ 0.35 for OS, p ϭ 0.19 for PFS). For OS, the younger patients showed an interesting trend in that OS appeared to be inferior with WBRT in CR patients (44. We also explored to what extent an inferior Karnofsky Performance Status (KPS) might account for the inferior outcome in the elderly. Table e-2 shows that the hazard ratios conferred by age changed only marginally after adjustment for KPS.
DISCUSSION Current trial concepts for PCNSL already stratify PCNSL treatment by age and aim for cure using aggressive multimodality treatments exclusively in the younger patient population. Only a few prospective trials including exclusively elderly patients with PCNSL have been published. How- Abbreviation: ITT ϭ intention-to-treat.
ever, the importance of age as a prognostic marker has been stressed repeatedly. 1, 14 In order to define future therapeutic strategies for elderly patients, we performed a comprehensive analysis of the data of the G-PCNSL-SG-1 study. This trial indicated that the omission of WBRT from primary HD-MTX-based chemotherapy does not compromise OS. We identified 126 patients who had entered the trial at the age of 70 or older. No other randomized and prospective study for patients with PCNSL has included a similar number of elderly patients. Despite the large number of patients, our analysis has its limitations. Due to the post hoc nature of the study and the lack of correction for multiplicity, the p values and type 1 errors have to be interpreted in a nonconfirmatory sense. Accordingly, the type 2 errors presented in the Methods have to be interpreted cautiously. Nevertheless, the G-PCNSL-SG-1 database provides a unique opportunity to determine the impact of age on the response to, toxicity of, and outcome with HD-MTX-based chemotherapy with or without WBRT. The results of this analysis provide a strong rationale for stratified approaches to PCNSL indeed.
As previously described, the toxicity of HD-MTX was acceptable in the majority of patients irrespective of their age. 15 Using a dosing algorithm for HD-MTX based strictly on the glomerular filtration rate, the treatment was well-tolerated even in elderly patients, and only leukopenia was observed more frequently in this population, suggesting that chemotherapy can be administered safely to the majority of elderly patients and confirming data from previous smaller patient cohorts. 16 However, the response rate to HD-MTXbased chemotherapy was lower in the elderly, and it is conceivable that this decreased activity of primary chemotherapy is linked to the higher frequency of MTX dose reductions in the elderly (table 3) . Alternatively, or in addition, PCNSL in the elderly may represent a biologically different, more treatmentresistant disease. WBRT and HD-MTX can be associated with significant neurotoxicity, particularly in elderly patients with PCNSL. The available dataset from G-PCNSL-SG-1 did not allow for a comprehensive analysis regarding this matter. Moreover, the major challenge in the elderly is still limited efficacy of treatment rather than treatment-related (neuro)toxicity. Yet, with hopefully more effective treatments, this issue warrants consideration in future clinical trials in the elderly.
OS was much more different between the younger and the elder patients than PFS (table 4, figure) . Several factors may contribute to this: the primary treatment Abbreviations: CI ϭ confidence interval; CR ϭ complete response; ITT ϭ intention-to-treat; OS ϭ overall survival; PFS ϭ progression-free survival; PP ϭ per protocol; WBRT ϭ whole brain radiotherapy. was not too effective, younger patients were more often treated at relapse (table 3) , and relapsed PCNSL in younger patients might be more responsive to therapy. Our analysis also revealed that elderly patients were more likely to be treated other than randomized when they progressed early. Yet, it is noteworthy that elderly patients received the same benefit from WBRT given as salvage in the setting of PD during primary HD-MTXbased chemotherapy.
The dramatic difference in PFS in elderly patients achieving a CR was a major finding. The clinical consequence from this observation is clear: we must focus on effective maintenance regimens for elderly PCNSL patients in CR. The design of future clinical trials for elderly PCNSL patients might, e.g., include a "maintenance regimen" such as a prolonged administration of HD-MTX at longer intervals. The biological implications of this observation of inferior outcome in the elderly remain unclear. Is PCNSL a different disease in the elderly or are there agespecific sanctuaries of lymphoma cells that are not adequately targeted by treatment? Or does the immune system participate in the maintenance of CR in the younger, but not in the presumably less immunocompetent elderly patients? Answers to questions require carefully designed cooperative group studies with elaborate translational research programs that will continue to be challenging, given the low incidence and heterogeneous course of PCNSL.
